## NICE GUIDANCE Hepatitis B and C: ways to promote and offer testing

## **10<sup>th</sup> Meeting of the Programme Development Group**

## Thursday 12<sup>th</sup> April 2012

## Floor 24, City Tower, Manchester, M1 4BD

Attendees:	<ul> <li>Programme Development Group (PDG) Members: Matt Hickman, Neil Connelly, James Windsor, April Wareham, Opal Greyson, Deirdre Kelly, Salim Khakoo, Danny Morris, Erika Duffell, Will Irving, Emily Kam-Yin Lam, Kylie Reed.</li> <li>NICE: Antony Morgan, Alastair Fischer, Clare Wohlgemuth, Kay Nolan, Victoria Axe, Hilary Chatterton</li> </ul>
Apologies:	<ul> <li>PDG Members: Richard Grieve, Cristina Osorio, Jeremy Jones, Nat Wright, Daniela De Angelis, Kate Drysdale, Vijay Anand.</li> <li>NICE: James Jagroo</li> </ul>

Author	Victoria Axe
File Ref	Hepatitis PDG 10: Final minutes
Version	Final
Audience	PDG members, NICE team, the public (via web publication)

Item		Action
1. Welcome and introduction	<ul> <li>The Chair welcomed the group to the tenth committee meeting.</li> <li>The Chair informed the group that this would be the last meeting before the consultation on the guidance. The PDG will have one final chance to amend the guidance via email before the consultation begins.</li> <li>The Chair noted that the following members had given their</li> </ul>	
	apologies: Richard Grieve, Cristina Osorio, Jeremy Jones, Nat Wright, James Jagroo, Daniela De Angelis, Kate Drysdale and Vijay Anand.	
2. Declarations of Interest	The committee were asked if they had any further conflicts of interest to declare.	
	Danny Morris declared that he is the Royal College of General Practitioners Substance Misuse and Associated Health Unit Clinical Lead for the Hepatitis B and C Certificate.	
3. Notes of the last meeting	The minutes of the last meeting were discussed and minor amendments were made.	
	The minutes were signed off as an accurate account of the last meeting.	
4. Where are we now	Antony Morgan (AM) gave a presentation on where the committee are now. AM explained the aims of the meeting and the process that the guidance will follow prior to consultation.	
	AM asked the committee to provide feedback to NICE on how they felt the group have worked during this time.	
	Action: PDG members to email AM with feedback	PDG
	AM gave the group the key dates between now and the publication of the guidance.	
	AM asked the committee to keep in mind equity issues when forming the recommendations.	
	AM asked the committee to think about which order they would like the considerations to be placed in.	
	Kay Nolan (KN) discussed finalising the target population within the guidance. KN asked the group if they were happy to go with one type of population. The group suggested changing the target population to "adults and children who are at increased risk of infection of hepatitis B or C" instead of "people who are at increased risk of chronic hepatitis B or	

	C".	
	KN asked the group to think of this target audience when looking through the draft recommendations.	
5. Draft recommendati ons	The committee ran through the draft guidance and suggested amendments to each recommendation.	
	Action: Deirdre Kelly and Opal Greyson to work together to define the term "close contacts" which will be placed in the glossary.	DK and OG
	The committee looked at all draft recommendations and gave thought to gaps in the evidence, any amendments needed, equity issues, the evidence base and considerations.	
	Action: NICE Team to redraft the recommendations in line with the PDG's suggestions prior to emailing the PDG in May.	NICE Team
	Deirdre Kelly left the meeting at 1pm.	
	Will Irving left the meeting at 3pm.	
	Salim Khakoo (SK) gave a presentation on Fibroscans. The members of the PDG asked SK questions in regards to his presentation.	
7. Next steps	AM reminded the PDG that they will receive the final draft guidance on May 4 and will be asked to comment prior to consultation.	
8. AOB	There was no other business.	
9. Close	The meeting closed at 15.40 pm	